RP Cure Tracker

Trials / NCT04671433

Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Completed Phase 3 Gene therapy

Sponsor
MeiraGTx Ocular UK Ltd
Treatment
Genetic: AAV5-hRKp.RPGR; Genetic: AAV5-hRKp.RPGR
Gene
RPGR
Conditions
X-Linked Retinitis Pigmentosa
Ages
3 Years to no upper limit
Enrollment
105 participants
Started
2020-12-04
Main results expected
2024-09-30
Results posted
Not yet
Record last updated
2026-09-24

What the study is testing

A clinical trial of AAV5-RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)

Where it runs

Belgium (1)
Canada (1)
Denmark (1)
France (1)
Israel (1)
Italy (4)
Netherlands (2)
Spain (1)
Switzerland (2)
United Kingdom (4)
United States (10)

Open on ClinicalTrials.gov for contacts and eligibility